News Releases

July 23, 2018
Bioventus Enters Into Definitive Agreement to Divest BMP Program
DURHAM, NC – July 23, 2018 – Bioventus , a global leader in orthobiologic solutions, has entered into a definitive agreement to divest its next generation bone morphogenetic protein (BMP) development program to a new company formed by Viscogliosi Brothers, LLC (VB) , a private equity investment
Read More
March 5, 2018
Bioventus Launches DUROLANE in the US
DURHAM, NC – March 5, 2018 – Bioventus , a global leader in orthobiologic solutions, today launched DUROLANE , its single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis (OA) .
Read More
February 26, 2018
Bioventus to Co-Develop Next Generation Bone Allograft with LifeLink
DURHAM, NC – February 26, 2018 – Bioventus , a global leader in orthobiologic solutions, has entered into an agreement with LifeLink Tissue Bank, a division of LifeLink Foundation, Inc. headquartered in Tampa, FL, to co-develop a next generation bone allograft solution for use in spine and trauma
Read More
February 12, 2018
Bioventus to Continue Distributing SUPARTZ FX Through 2028
DURHAM, NC – February 12, 2018 – Bioventus , a global leader in orthobiologic solutions, has entered into an extension of its agreement with Seikagaku Corporation to continue distributing SUPARTZ FX ™ , a five – injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of
Read More
January 25, 2018
Bioventus Launches New Website for EXOGEN®
DURHAM, NC– January 25, 2018 – Bioventus , a global leader in orthobiologics, today has launched a new version of EXOGEN.com , the product website for its EXOGEN Ultrasound Bone Healing System . EXOGEN uses safe, effective low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural
Read More
Displaying 121 - 126 of 126